Achieve Life Sciences IncNASDAQ:ACHV
- LAST PRICE4.5000
- TODAY'S CHANGE (%)0.0900 (2.0408%)
- Bid / Lots4.2300/ 1
- Ask / Lots4.7000/ 1
- Open / Previous Close4.4200 / 4.4100
- Day Range
- 52 Week Range
- Volume51,613
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ACHV |
|---|---|---|
| 09:32 ET | 137 | 4.42 |
| 09:38 ET | 750 | 4.4011 |
| 09:39 ET | 2553 | 4.36 |
| 09:41 ET | 2600 | 4.48 |
| 09:43 ET | 100 | 4.38 |
| 09:50 ET | 2130 | 4.35 |
| 09:52 ET | 600 | 4.35 |
| 10:03 ET | 100 | 4.41 |
| 10:06 ET | 400 | 4.3801 |
| 10:14 ET | 200 | 4.41 |
| 10:15 ET | 3300 | 4.5 |
| 10:33 ET | 348 | 4.5899 |
| 10:35 ET | 100 | 4.5442 |
| 10:39 ET | 100 | 4.54 |
| 10:44 ET | 215 | 4.54 |
| 11:02 ET | 400 | 4.545 |
| 11:04 ET | 100 | 4.51 |
| 11:15 ET | 100 | 4.555 |
| 11:20 ET | 1451 | 4.52 |
| 11:29 ET | 743 | 4.49 |
| 12:21 ET | 117 | 4.515 |
| 12:41 ET | 100 | 4.5 |
| 01:26 ET | 1017 | 4.55 |
| 01:30 ET | 100 | 4.58 |
| 01:57 ET | 495 | 4.55 |
| 02:11 ET | 1842 | 4.56 |
| 02:27 ET | 2151 | 4.53 |
| 02:40 ET | 400 | 4.53 |
| 02:49 ET | 400 | 4.55 |
| 02:58 ET | 100 | 4.53 |
| 03:16 ET | 695 | 4.53 |
| 03:39 ET | 300 | 4.54 |
| 03:45 ET | 100 | 4.525 |
| 03:54 ET | 1454 | 4.51 |
| 03:57 ET | 8301 | 4.48 |
| 03:59 ET | 894 | 4.5 |
Apr 17, 2024
DJ Achieve Life Sciences Initiated at Buy by JonesTrading, from 10:24AM ET on Wednesday Apr 17, 2024 by Dow Jones
10:24AM ET on Wednesday Apr 17, 2024 by Dow Jones
Apr 11, 2024
Achieve Life Sciences to Present at Life Science Innovation Northwest 2024 Conference, from 8:00AM ET on Thursday Apr 11, 2024 by Dow Jones
8:00AM ET on Thursday Apr 11, 2024 by Dow Jones
Apr 1, 2024
DJ Achieve Life Sciences Price Target Maintained With a $18.00/Share by Oppenheimer, from 9:24AM ET on Monday Apr 01, 2024 by Dow Jones
9:24AM ET on Monday Apr 01, 2024 by Dow Jones
Mar 28, 2024
*DJ Achieve Life Sciences 4Q Loss/Shr 26c >ACHV, from 4:01PM ET on Thursday Mar 28, 2024 by Dow Jones
4:01PM ET on Thursday Mar 28, 2024 by Dow JonesAchieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2023 and Provides Corporate Update, from 4:01PM ET on Thursday Mar 28, 2024 by Dow Jones
4:01PM ET on Thursday Mar 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Achieve Life Sciences Inc | 151.1M | -2.9x | --- |
Cytodyn Inc | 149.1M | -2.7x | --- |
Zura Bio Ltd | 144.3M | -0.8x | --- |
Regulus Therapeutics Inc | 144.0M | -1.4x | --- |
Rezolute Inc | 142.1M | -2.6x | --- |
Candel Therapeutics Inc | 162.6M | -4.5x | --- |
Company Information
Achieve Life Sciences, Inc. is a late-stage clinical pharmaceutical company. The Company is engaged in development and commercialization of cytisinicline for smoking cessation and nicotine addiction. The Company’s product candidate, cytisinicline, is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a well-defined, dual-acting mechanism of action that is both agonistic and antagonistic. Cytisinicline is a partial agonist that binds with high affinity to the alpha-4 beta-2, nicotinic acetylcholine receptors in the brain. Through its dual-acting partial agonist/partial antagonist activity, cytisinicline helps reduce nicotine cravings, withdrawal symptoms and reward and satisfaction associated with smoking. It is developing cytisinicline as an aid to smoking cessation and treatment for nicotine addiction to address the limitations of both prescription drugs and of over the counter (OTC) products.
Contact Information
- Headquarters
- 22722 29TH DR. SE, SUITE 100SEATTLE, WA, United States 98021
- Phone
- 425-686-1500
- Fax
- 302-636-5454
Executives
- Executive Chairman of the Board
- Richard Stewart
- President, Director, Chief Medical Officer
- Cindy Jacobs
- Chief Executive Officer, Director
- John Bencich
- Principal Accounting Officer
- Jerry Wan
- Independent Director
- Stuart Duty
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $151.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 34.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.25 |
EPS | $-1.53 |
Book Value | $-0.07 |
P/E Ratio | -2.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
